1. Home
  2. SFST vs TRDA Comparison

SFST vs TRDA Comparison

Compare SFST & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern First Bancshares Inc.

SFST

Southern First Bancshares Inc.

N/A

Current Price

$51.32

Market Cap

421.9M

Sector

Finance

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$12.73

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SFST
TRDA
Founded
1999
2016
Country
United States
United States
Employees
N/A
183
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.9M
481.6M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
SFST
TRDA
Price
$51.32
$12.73
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$64.00
$20.00
AVG Volume (30 Days)
57.5K
191.6K
Earning Date
04-23-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
94.76
N/A
EPS
3.72
N/A
Revenue
$6,282,000.00
$25,421,000.00
Revenue This Year
$10.47
$51.37
Revenue Next Year
$12.19
$46.98
P/E Ratio
$14.05
N/A
Revenue Growth
12.99
N/A
52 Week Low
$29.80
$4.93
52 Week High
$62.00
$12.93

Technical Indicators

Market Signals
Indicator
SFST
TRDA
Relative Strength Index (RSI) 32.73 59.95
Support Level $50.27 $9.59
Resistance Level $52.60 N/A
Average True Range (ATR) 1.94 0.86
MACD -0.99 0.09
Stochastic Oscillator 12.68 84.15

Price Performance

Historical Comparison
SFST
TRDA

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: